Nathalie Jetté1, Farnaz Amoozegar1, Scott B Patten1. 1. Department of Clinical Neurosciences (NJ, FA), Hotchkiss Brain Institute (NJ, FA, SBP), Department of Psychiatry (SBP), Mathison Health Centre (SBP), Department of Community Health Sciences (NJ, FA, SBP), and O'Brien Institute for Public Health (NJ, FA, SBP), Cumming School of Medicine, University of Calgary, Canada.
Abstract
PURPOSE OF REVIEW: To provide an overview of the epidemiology of depression in chronic neurologic conditions that can affect individuals throughout the lifespan (epilepsy, migraine, multiple sclerosis [MS]) and examine depression screening tools for adults with these conditions. RECENT FINDINGS: Depression is common in neurologic conditions and can be associated with lower quality of life, higher health resource utilization, and poor adherence to treatment. It affects around 20%-30% of those with epilepsy, migraine, and MS, and evidence for a bidirectional association exists for each of these conditions. Depression screening tools generally perform well in neurologic conditions, but are not without limitations. SUMMARY: Depression is a major contributor to poor outcomes in epilepsy, migraine, and MS. Although psychiatric resources are scarce globally, this is no reason to ignore depression in neurologic conditions. Depression screening tools are available in neurology and should be considered in clinical practice.
PURPOSE OF REVIEW: To provide an overview of the epidemiology of depression in chronic neurologic conditions that can affect individuals throughout the lifespan (epilepsy, migraine, multiple sclerosis [MS]) and examine depression screening tools for adults with these conditions. RECENT FINDINGS: Depression is common in neurologic conditions and can be associated with lower quality of life, higher health resource utilization, and poor adherence to treatment. It affects around 20%-30% of those with epilepsy, migraine, and MS, and evidence for a bidirectional association exists for each of these conditions. Depression screening tools generally perform well in neurologic conditions, but are not without limitations. SUMMARY: Depression is a major contributor to poor outcomes in epilepsy, migraine, and MS. Although psychiatric resources are scarce globally, this is no reason to ignore depression in neurologic conditions. Depression screening tools are available in neurology and should be considered in clinical practice.
Authors: Mike P Kerr; Seth Mensah; Frank Besag; Bertrand de Toffol; Alan Ettinger; Kousuke Kanemoto; Andres Kanner; Steven Kemp; Ennapadum Krishnamoorthy; W Curt LaFrance; Marco Mula; Bettina Schmitz; Ludgers Tebartz van Elst; Julian Trollor; Sarah J Wilson Journal: Epilepsia Date: 2011-09-28 Impact factor: 5.864
Authors: Lydia Chwastiak; Dawn M Ehde; Laura E Gibbons; Mark Sullivan; James D Bowen; George H Kraft Journal: Am J Psychiatry Date: 2002-11 Impact factor: 18.112
Authors: Stephanie J Gill; Sara Lukmanji; Kirsten M Fiest; Scott B Patten; Samuel Wiebe; Nathalie Jetté Journal: Epilepsia Date: 2017-01-08 Impact factor: 5.864
Authors: Kirsten M Fiest; Scott B Patten; K Chelsea Altura; Andrew G M Bulloch; Colleen J Maxwell; Samuel Wiebe; Sophia Macrodimitris; Nathalie Jetté Journal: Epilepsy Behav Date: 2014-09-07 Impact factor: 2.937